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Background: By the year 2030 the percent of the population over the age of 65 years is   projected 
to range from 3.7% (in sub-Saharan Africa) to almost 22% (in Europe). Accompanying this unprec-
edented growth will be a significant increase in many of the disease processes or “comorbidities” 
associated with aging, not the least of which is hypertension. Global health care resources and 
economies in general will be stressed to breaking point if this condition is not dealt with in an 
aggressive and timely manner because the consequences of untreated hypertension such as stroke, 
myocardial infarction, and dementia are exceedingly costly in the long term.
Methods: To help focus attention on the worldwide epidemic of hypertension, the current 
literature and guidelines were reviewed, along with information on the various classes of 
medications indicated in the treatment of hypertension in the elderly.
Results: Recent, large, randomized trials indicate that hypertension in the elderly can and 
should be treated to lower the incidence of stroke, myocardial infarction, and chronic kidney 
disease. Although thiazide-type diuretics are the recommended first-line agents in most cases of 
uncomplicated hypertension, multiple drug classes have been shown to be useful. In addition, and 
where feasible, a multidisciplinary team approach has demonstrated the most durable results.
Conclusion: Thiazide diuretics should be the first-line agents in uncomplicated, isolated 
systolic hypertension. Starting at low doses and proceeding in a gradual manner, these agents 
have proven efficacy in decreasing the risk of stroke and cardiovascular events. It is now recom-
mended that these agents be used in low-dose combinations with other antihypertensive drug 
classes in patients who do not achieve target blood pressure (,140/90 mmHg).
Keywords: isolated systolic hypertension, pulse pressure, ambulatory blood pressure 
monitoring
Introduction
Until recent studies provided evidence-based data showing that hypertension (HTN) 
in the elderly can and should be treated, and that multiple agents are effective, the 
prevailing opinion was that “the treatment of hypertension is a difficult and almost 
hopeless task”. In fact, high blood pressure (BP) was believed to be a compensatory 
response to the narrowing of the coronary and cerebral vasculature that occurred with 
aging and as such should perhaps not even be “tampered” with.
Projections for the growth of the older US population estimate there will be 
82 million persons over 65 years (20% of the total population) and 19 million over 
85 years (24% of the population over 65 years) by the year 2050. This growth in the 
older population is a result not only of an increase in the overall population size but 
also a decline in several of the major causes of mortality. However, despite   aggressive Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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efforts directed at reducing the burden of cardiovascular 
disease, the age-related increase in BP combined with the 
increase in the aging population, portends a public health 
“tsunami”.
Control of HTN in the elderly is imperative, not only to 
reduce the risk of cardiovascular disease, stroke, and chronic 
kidney disease, but also the incidence of atrial fibrillation, 
congestive heart failure (CHF), and cognitive impairment. 
Multiple antihypertensive agents have proven useful in the 
elderly. It has been shown that a 10 mmHg reduction in 
systolic blood pressure (SBP) and a 5 mmHg reduction in 
diastolic blood pressure (DBP) significantly decrease the 
incidence of myocardial infarction, stroke, CHF, and overall 
mortality. Despite these findings, the rate of control of HTN 
is low, especially among the elderly, and reflects a need for 
more aggressive approaches, as well as improvements in the 
systems of care delivery. There is also a compelling need for 
research into the mechanisms of the age-related increase in 
BP and prevention of HTN in general.
Classification
Based on the current classification of HTN by the Joint 
National Committee on Prevention, Detection, Evaluation 
and Treatment of High Blood Pressure (JNC 7, Table 1)1 
the estimated prevalence of HTN in the population over 
65 years is 50%–75%. For women over 75 years this value 
exceeds 75%. In addition, data from the Framingham Heart 
Study show that over 20–25 years of follow-up, 85% of men 
and women with normal BP at age 55 years will develop 
HTN by the time they attain the age of their average life 
expectancy.2
Interestingly, the current classification of BP as set out by 
the JNC 7 makes no adjustment for age. JNC 7 incorporates 
research findings demonstrating that cardiovascular risk 
increases fairly linearly with increasing BP, and that this risk 
starts to increase above a BP level of 115/75 mmHg. In addition, 
there is now a category labeled “pre-  hypertension”, defined as 
SBP 120–139 mmHg or DBP 80–89 mmHg.   Isolated systolic 
hypertension (ISH), the most common HTN subtype in the 
older population, has been removed as a distinct category. 
Instead, in almost all cases, HTN in the older population can 
be categorized on the SBP level alone.
Age-related pathophysiologic 
changes
It is highly unlikely that a single etiology is the explanation 
for essential HTN, no matter what a person’s age. More 
probable is the contribution of multiple physiologic and life-
style factors. Those factors likely contributing to age-related 
increase in BP include increased arterial stiffness (especially 
of the large arteries),3 decreased baroreceptor sensitivity,4 
increased sympathetic nervous system activity,4 endothelial 
dysfunction,5 sodium sensitivity (decreased ability to excrete 
a sodium load),6 low plasma renin activity, insulin resistance, 
and the resulting effect on carbohydrate metabolism.7 Aldos-
terone may also be a significant contributor to HTN in later 
life.8 Lifestyle factors such as being sedentary, the presence 
of central adiposity, and a diet high in salt and fat are other 
contributors to HTN in the elderly.
Systolic HTN with an increased pulse pressure is the most 
commonly encountered form of HTN in the elderly and is 
associated with an increase in arterial stiffness.9 The degree 
of arterial stiffness has been shown to correlate with and pre-
dict the risk for adverse cardiovascular outcomes and overall 
mortality.10 Arterial stiffness can be determined noninvasively 
by techniques that measure pulse wave velocity between the 
carotid and femoral arteries. These measurements “span” 
the aorta and are therefore taken as a measure of aortic pulse 
wave velocity7 and stiffness. Recent studies have shown that 
despite comparable reductions in BP, antihypertensive agents 
from various classes have very different effects on aortic pulse 
wave velocity.11 This may explain why equivalent effects on 
lowering peripheral BP have not necessarily equated with 
improved clinical outcomes and why research is now focus-
ing more on agents that result in reduced stiffness of the 
large arteries. Therefore, age-related changes in the renin–
angiotensin–aldosterone system are being actively studied.
Aldosterone is known to play several important roles 
mediated by both genomic and nongenomic pathways. Min-
eralocorticoid receptors are widely distributed, not only in 
the vasculature but also within the myocardium and central 
nervous system (CNS). In addition, evidence is accumulating 
that adipose tissue produces aldosterone secretory factors that 
promote excessive adrenal aldosterone production leading 
to insulin resistance, inflammation, oxidative stress, and 
Table 1 JNC 7 classification of blood pressure levelsa
Category Systolic  
(mmHg)
Diastolic   
(mmHg)
Normal ,120 and ,80
Prehypertension 120–139 or 80–89
Hypertension
  Stage 1 140–159 or 90–99
  Stage 2 .160 or .100
aAdapted from JNC 7 express: The Seventh Report of the Joint National Committee 
on  Prevention,  Detection,  evaluation,  and  Treatment  of  High  Blood  Pressure. 
Bethesda, MD: National High Blood Pressure education Program, National Heart, 
Lung and Blood institute, National institutes of Health, US Department of Health 
and Human Services; May 2003.1Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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sodium retention.8 Even within physiologic ranges, higher 
levels of plasma aldosterone have been shown to predispose 
individuals to developing HTN in the future.12
Other pathophysiologic changes characteristic in the 
elderly and important when contemplating treatment include 
the development of autonomic changes, such as decreased 
baroreceptor sensitivity and increased sympathetic nervous 
system activity.4 Under resting conditions, older individu-
als usually have no difficulty maintaining BP and adequate 
cerebral perfusion. However, with intravascular fluid shifts 
such as those occurring upon assuming an upright position 
or postprandially, or with exposure to vasodilator agents, the 
older individual is less able to compensate, and significant 
hypotension and decreased cerebral perfusion may occur. 
Due to baroreceptor insensitivity, larger changes in BP 
are required in order to initiate an appropriate compensa-
tory increase in heart rate. In addition, the variability in 
BP increases with increasing age. The age-related increase 
in sympathetic nervous system activity may contribute 
to HTN through increased alpha-adrenergic receptor 
responsiveness.4
Other mechanisms involved in the increase in BP with 
aging include changes in the vascular endothelium resulting 
in increased vascular resistance. A decrease in the production 
of endothelial-derived nitric oxide impairs vasodilation and 
has been shown to correlate with aging and the develop-
ment of HTN.5 A decrease in the kidney’s ability to excrete 
a sodium load, related to decreases in renal blood flow and 
glomerular filtration, is another potential contributor to the 
observed increase in BP with aging. Salt sensitivity (defined 
as an increase in mean arterial BP $ 5 mmHg during a high 
versus a low sodium diet) is a finding in up to two-thirds of 
older hypertensive individuals.
Evaluation and diagnosis
Because BP is more variable in the elderly, HTN should 
never be diagnosed on the basis of a single measurement. At 
the initial visit, supine, sitting, and upright BPs should be 
determined and performed in both arms. The importance of 
a quiet environment (ideally using an automated instrument 
that obtains 5–6 measurements at 1-minute intervals with 
no medical personnel present in the room), sitting comfort-
ably in a chair with the back supported and both feet flat on 
the floor, no intake of caffeine or use of tobacco for at least 
30–45 minutes before measurement, appropriate cuff size, 
placement on bare skin, and resting with the arm supported 
at heart level for 5–10 minutes, cannot be overemphasized. 
Failure to follow these instructions can lead to significant, 
but false, elevations in BP. Three to five separate measure-
ments should be made on each of 3 separate visits and the 
average calculated. Consideration must also be given to the 
existence of an auscultatory gap. Therefore, the maximum 
inflation pressure should be determined by palpating the 
radial or brachial pulse during cuff inflation and inflating well 
above the point where the pulse disappears. Determining the 
presence of postural hypotension, ie, a decrease of at least 
20 mmHg in the SBP or 10 mmHg in the DBP in association 
with reported symptoms of dizziness or light-headedness 
within the first 2–5 minutes of assuming an upright posture, 
is also necessary in order to avoid increasing the risk of falls 
with the addition of antihypertensive medications.
Another consideration in evaluating HTN is the existence 
of office (“white-coat”) HTN. This should be suspected 
when BP values determined in the clinic are consistently 
greater than those measured at home. In these cases, serious 
consideration should be given to either carefully obtained 
home values using an appropriately calibrated BP monitor 
or obtaining 24-hour ambulatory BP measurements. The 
technique of 24-hour ambulatory BP monitoring is useful for 
several reasons.13 Firstly, it defines daytime and nocturnal 
as well as the average BP over an entire 24-hour period. 
Target organ damage (eg, left ventricular hypertrophy 
[LVH], decreased renal function/microalbuminuria, carotid 
plaque, or hypertensive retinopathy) is best correlated with 
the 24-hour average value. Secondly, patients who fail to 
decrease their average nocturnal SBP by at least 10% of the 
average daytime SBP value (non-dippers) have been found to 
possess a more adverse cardiovascular risk profile compared 
with those who do drop by .10% (dippers).14
In order to obtain reliable home values it is imperative 
that patients be educated in appropriate BP measurement 
techniques. As with office measurement, the patient needs to 
be sitting quietly for 5–10 minutes with his or her back sup-
ported in a chair with feet flat on the floor and arm supported 
at heart level. Morning and evening measurements should be 
made in triplicate, with the first discarded and the last two 
averaged. This should be done over a 7-day period, with the 
first 2 days discarded and the last 5 averaged. A similar tech-
nique can be used when/if treatment is initiated but with only 
once-a-day measurements taken just before administration of 
the majority of antihypertensive medication(s).
As with the younger population, greater than 90% of the 
elderly with high BP have essential HTN. With few excep-
tions, the same guidelines used in younger patients should 
be applied in the older population when secondary forms of 
HTN are suspected. Because ISH is the predominant form Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in the elderly, those who present with isolated diastolic 
HTN deserve careful consideration, with attention given to 
a renovascular etiology. Because of the propensity toward 
polypharmacy, the importance of a thorough medication 
review cannot be overemphasized. Attention should be paid 
to those medications known to increase BP, particularly corti-
costeroids and non-steroidal anti-inflammatory drugs, includ-
ing the Cox-2 inhibitors. The high prevalence of obstructive 
sleep apnea in the elderly hypertensive population dictates 
this condition should be considered as a cause of high BP. 
Finally, although rare, the incidence of pheochromocytoma 
has been shown in autopsy studies to increase with age.
The evaluation of the older hypertensive patient is not 
complete without a thorough investigation of target organ 
damage, cardiovascular risk assessment, and identifica-
tion of comorbid conditions that may impact the choice of 
antihypertensive therapy. The presence or absence of renal 
dysfunction, proteinuria/microalbuminuria, hypertensive 
retinopathy, and LVH should be determined. Cardiovascular 
risk should be assessed based on age, tobacco and/or alcohol 
use, lipid profile, salt and fat intake, and level of physical 
activity. Although somewhat controversial, factors consistent 
with the metabolic syndrome (impaired fasting glucose, HTN 
or its treatment, LDL , 40 in men and ,50 in women, waist 
circumference .35 inches in men and .40 inches in women, 
and hypertryglyceridemia) should also be determined and 
addressed.
Treatment
Data from multiple, randomized, placebo-controlled tri-
als overwhelmingly support the treatment of HTN in the 
elderly and that this treatment is safe and effective. The 
SHEP (Systolic Hypertension in the Elderly Program) trial 
followed 4736 individuals (average age 72 years) with ISH 
(average baseline SBP 170 mmHg; average DBP 77 mmHg) 
for 4.5 years (average follow-up). Those randomized to 
active therapy (chlorthalidone 12.5 mg up to 25 mg/day, 
followed by atenolol 25 mg up to 50 mg/day if indicated) 
achieved an average SBP of 143 mmHg compared with 155 
mmHg in the placebo group. Active treatment reduced the 
incidence of total stroke by 36% and major cardiovascular 
events by 32%.15 The Medical Research Council (MRC) 
trial of treatment of HTN in older adults randomized 4396 
patients aged 65–74 years from 226 general practices to 
treatment with a diuretic (hydrochlorothiazide 25 mg or 
50 mg plus amiloride 2.5 mg or 5 mg daily), a beta-blocker 
(atenolol 50 mg daily) or placebo. Mean SBP at baseline was 
160–209 mmHg, mean DBP , 115 mmHg. After a mean 
follow-up of 5.8 years, active treatment (diuretic and beta-
blocker groups combined) showed a 25% reduction in stroke, 
a 19% reduction in coronary events, and a 17% reduction 
in all cardiovascular events. The study also found that after 
adjustment for baseline characteristics, the diuretic group 
showed significant reductions in stroke (31%), coronary 
events (44%), and all cardiovascular events (35%), whereas 
the beta-blocker group showed no significant reductions in 
the same endpoints.16 At a median follow-up of 2 years in 
patients over the age of 60 years with ISH (baseline SBP 
160–219 mmHg, DBP , 95 mmHg), the Syst-Eur (Systolic 
Hypertension in Europe) trial demonstrated a 42% reduc-
tion in total stroke, 44% reduction in non-fatal stroke, and 
a 31% reduction in fatal/non-fatal cardiovascular endpoints 
in the active treatment group compared with those on 
placebo. Active treatment consisted of nitrendipine 10–40 
mg/day with the possible addition of enalapril 5–20 mg/
day and/or hydrochlorothiazide 12.5–25 mg/day, and this 
regimen achieved a 23/7 mmHg reduction in SBP and DBP, 
  respectively, compared with 13/2 mmHg in the placebo 
group.17 Overall, significant reductions in mortality (12%–
25%), stroke (35%), and myocardial infarction (25%), as 
well as chronic kidney disease (CKD) and CHF, have been 
demonstrated with active therapy. Put in terms of the number 
needed to treat (assuming a decrease in SBP of 12 mmHg 
over 10 years), anywhere from 9 (highest-risk group) to 
81 (lowest-risk group) patients would need to be treated 
to prevent one death.
Until completion of the recent Hypertension in the Very 
Elderly Trial (HYVET), few randomized controlled trials of 
HTN included subjects over the age of 80 years and fewer 
still included those over 85 years of age. HYVET randomized 
3845 individuals over 80 years of age to either extended-
  release indapamide with the addition of perindopril (to 
achieve a target SBP , 150 mmHg) or placebo and was halted 
early when the data safety monitoring committee observed 
a 21% reduction in total mortality (absolute risk reduction 
2.2%, number needed to treat = 45 over a median 1.8-year 
period) in the treatment group. The intervention group also 
demonstrated significant reductions in fatal and non-fatal 
stroke, CHF, and cardiovascular events.18 HYVET subjects 
were generally healthy, community-dwelling older adults 
with a standing BP of .140 mmHg; those with dementia, 
nursing home residents, and those with an inability to walk 
were excluded. Therefore, it is important to note that results 
cannot be extrapolated to the frail elderly. In   addition, a 
substudy of HYVET (HYVET-COG) that assessed   cognitive 
function and the rate of development of dementia showed Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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a similar incidence of dementia between intervention and 
control groups.
Having demonstrated that HTN in the elderly can and 
should be treated, it is important to consider general geriatric 
principles and individualize patient goals. The risk of the most 
common treatment-related side effect, ie, postural hypoten-
sion, must be balanced against any potential   benefits of treat-
ment. In general, SBP should remain the primary target of 
therapy because it is a stronger predictor of adverse outcomes 
than is DBP. A SBP of 135–140 mmHg (SBP , 130 mmHg 
in type 2 diabetes or CKD) should be the treatment goal, 
utilizing agents least likely to negatively impact functional 
status and quality of life. For example, if a patient’s seated 
SBP cannot be lowered to ,140 mmHg without inducing 
significant orthostasis, then a focus on standing SBP may be a 
more prudent approach. In cases of a markedly elevated SBP, 
an initial goal of ,160 mmHg is reasonable, provided there 
is no evidence of target organ damage, or signs or symptoms 
of a hypertensive emergency.
Concerns have been raised about lowering BP below a 
certain threshold and the potential for adverse outcomes. Some 
studies have shown increased mortality, particularly with regard 
to DBP, below a certain threshold (the J-shaped curve). Post hoc 
analysis of the Systolic Hypertension in the Elderly trial19 
suggested that DBP , 70 mmHg was associated with more 
cardiovascular events, but only in those with a history of coro-
nary artery disease (CAD). Diastolic BP as low as 55 mmHg 
was not associated with increased cardiovascular mortality, but 
noncardiovascular mortality was increased (hazard ratios were 
higher). It is therefore prudent to avoid aggressive lowering of 
DBP (eg, ,70 mmHg), especially in individuals with CAD. 
Diastolic BP lower than this value is related to increased pulse 
pressure which, in turn, reflects increased arterial stiffness. 
Subsequent decreases in endocardial perfusion would then lead 
to tissue ischemia and an expected increased risk of adverse 
coronary and cerebrovascular events.
Nonpharmacologic approaches
Nonpharmacologic or lifestyle interventions can have sig-
nificant BP lowering effects and remain important adjuncts 
to drug therapy. In addition to potentiation of pharmacologic 
therapy, a decrease in other cardiovascular risk factors may be 
observed. Because the typical physiologic profile of the older 
hypertensive individual includes obesity, salt sensitivity, and 
lack of exercise, interventions directed at these characteris-
tics can be expected to have a significant impact (Table 2). 
Weight reduction, aerobic exercise, and a decrease in sodium 
and alcohol intake can each result in up to a 10 mmHg 
decrease in SBP which is equivalent to that achieved with 
monotherapy. Dietary sodium restriction (100–200 mEq/day) 
and weight loss in older hypertensive patients were studied in 
the Trial of Non-Pharmacologic Intervention in the Elderly.20 
The intervention group achieved an average 40 mmol/day 
reduction in sodium intake and an average 4 kg weight loss 
which were associated with a 30% decrease in the need to 
reinitiate antihypertensive therapy. In general, in elderly Stage 
1 hypertensive patients without diabetes, a 6-month trial of 
nonpharmacologic interventions is warranted as the first step 
in the treatment algorithm.
Pharmacologic interventions
In addition to the nonpharmacologic interventions discussed, a 
general approach to antihypertensive therapy includes the use 
of agents based on a patient’s comorbidities (eg, diabetes, CHF, 
CAD), a low-dose diuretic in uncomplicated HTN, starting at 
half the usual dosage and increasing slowly, a focus on SBP, 
avoiding excessive lowering of DBP, and accounting for indi-
vidual patient goals (Table 3). Racial and ethnic background 
must also be taken into consideration. Given these consider-
ations, the initial agent in simple, uncomplicated Stage 1 HTN 
will usually be a low-dose thiazide-type diuretic. In patients 
with a SBP . 20 mmHg above their target, it is likely that 
2 drugs will need to be initiated. Current   recommendations 
suggest combinations of a low-dose   thiazide diuretic with an 
Table 2 Nonpharmacologic therapies in stage 1 hypertension
•  weight loss with a focus on reduction of central adiposity
•    Aerobic exercise (goal 30 minutes/day, 5 days/week) combined with 
strength training
•  Smoking cessation
•  Moderation of alcohol intake (two drinks per day in men, one in women)
•    Modification of diet to decrease sodium, cholesterol, and saturated fat 
intake while maintaining adequate potassium, magnesium, and calcium 
intake
Table 3 General approach to pharmacologic therapy
•  Base therapy on pre-existing comorbidities, eg, diabetes, heart failure,CAD
•  Begin with a low-dose diuretic in uncomplicated hypertension
•    Begin therapy at half the usual dose and increase slowly, consider 
low-dose combination  therapy if goal SBP is not met on single-agent 
therapy
•  Focus on systolic blood pressure and patient comorbidities
•  Avoid excessive lowering of diastolic blood pressure (,70 mmHg)
•    Adjust goals when adverse events (eg, postural hypotension, postprandial 
hypotension) cannot be avoided
•    Continue and emphasize nonpharmacologic therapies throughout 
treatment 
Abbreviations: CAD, coronary artery disease; SBP, systolic blood pressure.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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angiotensin-converting enzyme inhibitor (ACEI), angiotensin 
receptor blocker (ARB), or long-acting calcium channel 
antagonist (CCA). Many preparations are available combined 
into a single tablet which would improve ease of administra-
tion and compliance. More recently, evidence is beginning 
to demonstrate that BP reductions may be greater and side 
effects lower with low-dose combinations of 2 or more anti-
hypertensive agents than with a single agent increased to full 
dose. As there is no universal agreement on the approach to 
choosing alternative agents or combination therapy, these deci-
sions should be based on a patient’s comorbidities, weighted 
with the advantages and disadvantages of a specific drug. In 
general, centrally acting agents (eg, clonidine, methyldopa) 
and direct vasodilators (minoxidil), due to their CNS side 
effects (sedation) and propensity to cause significant ortho-
static hypotension, should be avoided. Finally, beta-blockers 
are best avoided in the older hypertensive patient without a 
specific indication, such as CAD. In the older population, 
beta-blockers have been associated with no reduction in the 
risk of stroke or coronary events.13
Thiazide-type diuretics
Several properties of the thiazide-type diuretics have led 
to them being recommended as first-line therapy in most 
older adults with uncomplicated Stage 1 HTN. At low doses 
(,25 mg/day of hydrochlorothiazide or equivalent) these 
agents have been demonstrated in randomized controlled 
trials to reduce mortality, stroke, and cardiovascular events 
in the older hypertensive population.21 In addition, they have 
fewer side effects of hypokalemia, hyperuricemia, hypo-
magnesemia, hypertriglyceridemia, and glucose intolerance 
when used at recommended doses, with low cost and a wide 
therapeutic index, along with once-daily dosing. There is 
good synergy with agents of different classes (eg, ACEIs, 
ARBs, and CCAs) and most importantly in the elderly, these 
drugs preferentially lower SBP relative to DBP. Finally, it is 
important to note that maintaining potassium levels is key in 
order to reduce the potential for arrhythmias, because higher 
doses have been shown to increase the incidence of sudden 
cardiac death,22 as well as impairment of glucose tolerance. 
Also, this class is often ineffective at serum creatinine levels 
.2 mg/dL or creatinine clearance below 30–40 mL/min.
Angiotensin-converting enzyme 
inhibitors
This class of medication (eg, lisinopril 10–40 mg/day or 
equivalent), shown to be effective in the lowering of BP in 
the elderly, is also generally well tolerated and represents 
an acceptable alternative first-line therapy or in combination 
with a thiazide-type diuretic. These agents possess a favor-
able safety profile and lack significant CNS or metabolic 
side effects. In particular, the ACEIs have shown significant 
benefits in patients with diabetes (particularly with coexistent 
microalbuminuria) and those with left ventricular systolic 
dysfunction. In several clinical conditions, this class is asso-
ciated with preservation of renal function. Generalized side 
effects include cough, angioedema, hyperkalemia (particu-
larly in the setting of renal insufficiency or in combination 
with nonsteroidal anti-inflammatory drugs or potassium-
sparing diuretics), and acute renal failure in patients with 
significant bilateral renal artery stenosis. These agents are 
contraindicated in pregnancy.
Angiotensin receptor blockers
To date, there are no randomized controlled trials compar-
ing ARBs with diuretics and their effects on treatment out-
comes in the elderly. A single meta-analysis has suggested 
that therapy with diuretics is superior to that with ARBs 
for most outcomes. As a result, this class is not generally 
recommended as first-line therapy in uncomplicated HTN. 
Rather, they should be considered in those patients with 
diabetes, CHF, or chronic kidney disease who are intolerant 
of ACEIs. Angioedema is considered rare with ARBs and 
they are not a cause of cough.
Calcium channel antagonists
Although all three chemical classes of CCAs have shown 
effectiveness in lowering BP in the older hypertensive 
patient, it is the long-acting dihydropyridine class that has 
been the most widely studied. Significant reductions in stroke 
risk in older hypertensive patients were demonstrated in 
the Systolic Hypertension in Europe23 and China Trials.24 
Results from patients with very high cardiac risk enrolled 
in the Avoiding Cardiovascular Events through Combina-
tion Therapy in Patients Living with Systolic Hypertension 
(ACCOMPLISH) trial demonstrated the superiority of an 
ACEI-CCA (amlodipine) combination over an ACE-thiazide 
combination with regard to a decrease in cardiovascular 
events despite comparable BP-lowering effects.25 As a result 
of age-related pharmacokinetic changes (decreased clearance 
and increased plasma levels), lower CCA dosages should be 
used in the elderly. It should be emphasized that the long-
acting formulations are preferred, and that there is no role for 
short-acting CCAs in the treatment of HTN due to their pro-
pensity to lower SBP rapidly. Side effects include headache, 
lower extremity edema, gingival hyperplasia, worsening of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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gastroesophageal reflux symptoms due to relaxation of the 
lower esophageal sphincter, and constipation.
Beta receptor antagonists
Review of data from randomized controlled trials has ques-
tioned the efficacy of beta-receptor antagonists in the treat-
ment of older individuals with HTN. These agents appear 
to be less effective than low-dose thiazide diuretics with 
regard to improving BP and cardiovascular outcomes as 
initial therapy, and are more likely to be discontinued due to 
adverse side effects. As a result, this class is designated as a 
second-line therapy by JNC 7 and should not be considered 
as first-line in uncomplicated HTN in the elderly. Clearly, 
these agents are indicated in the older HTN population with 
certain comorbidities, such as symptomatic CAD, in sec-
ondary prevention after myocardial infarction, and in some 
patients with systolic dysfunction.
Alpha receptor antagonists
Although this class has been demonstrated to reduce periph-
eral vascular resistance and lower BP, the development of 
symptomatic postural hypotension has severely limited their 
utility, particularly in the elderly. In addition, data from the 
Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT) showed that subjects random-
ized to doxazosin had a 2-fold higher risk of hospitalization 
for CHF compared with those randomized to the diuretic 
arm.21 These medications may be considered as additional 
therapy, particularly in older hypertensive men with benign 
prostatic hypertrophy.
Aldosterone antagonists
Initially developed as therapy for cirrhosis and primary 
hyperaldosteronism, and later as additional agents in the 
treatment of CHF, aldosterone antagonists may prove useful 
as first-line agents in the elderly with uncomplicated HTN. 
As with thiazide-type diuretics, the aldosterone antagonists 
preferentially lower SBP. In addition, this class antagonizes 
aldosterone’s metabolic effects of increasing sodium resorp-
tion, altering renal hemodynamics, and increasing afterload 
and vascular stiffness, all of which are important pathophysi-
ologic characteristics of geriatric HTN.
Follow-up visits
Follow-up visit frequency is based on the level of HTN 
at presentation and for most patients (except those with 
SBP . 180 mmHg), a visit frequency of once every 1–2 months 
for dosage adjustment is appropriate.   Achieving target BP 
levels rapidly (except in cases of hypertensive emergencies) 
is unnecessary and should be avoided because overtreatment 
may result in decreased cerebral and coronary perfusion, and 
subsequent postural or postprandial hypotension. At each 
visit, both supine and standing BPs should be determined. 
Adjustments to therapy may need to be based on standing 
values if postural hypotension is present. Before instituting 
an increase in dosage or an additional agent, the patient’s 
adherence to therapy should be thoroughly assessed. The use 
of medications that can worsen BP control (eg, nonsteroidal 
anti-inflammatory drugs, including Cox-2 agents, and corti-
costeroids) should also be reviewed.
If, after performing the above review, a patient’s BP is 
still not at target, then a careful increase in dosage, addi-
tion of another agent (thiazide if not already being used and 
renal function is appropriate with a calculated creatinine 
clearance of .30–40 mL/min), or switching to another 
class of medication can be considered. Continuing efforts 
at lifestyle modifications should be re-emphasized, along 
with counseling that several months may be needed to 
achieve the target value. In general, target BPs are the same 
as those in a younger population, and are outlined in JNC 
7. Provided there is no evidence for a significant orthostatic 
drop in SBP, a goal of ,140/90 mmHg is reasonable. In 
patients with diabetes   mellitus and/or CKD the goal becomes 
,130/80 mmHg.
As with the younger hypertensive population, if target 
BP is not achieved on a 3-drug regimen with documented 
compliance, then an evaluation for resistant or secondary 
HTN (renovascular, primary hyperaldosteronism, obstruc-
tive sleep apnea, renal artery stenosis, pheochromocytoma, 
Cushing’s) should be undertaken. Finally, after more than a 
year of stable BP control at target levels, consideration can 
be given to a step-down in therapy, especially in patients who 
have been successful in lifestyle modifications. Nevertheless, 
dosages should be decreased slowly and cautiously while 
maintaining close BP monitoring.
Hypertensive emergencies  
and urgencies
By definition, a hypertensive emergency involves an elevated 
BP (usually .180 mmHg systolic) in association with signs 
and/or symptoms of target organ damage. The resultant vas-
cular compromise of the affected organ may include hyper-
tensive encephalopathy, acute heart failure with pulmonary 
edema (flash pulmonary edema), dissecting aortic aneu-
rysm, acute renal failure, and unstable angina.   Management 
requires acute hospitalization for   administration of parenteral Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  antihypertensives, with continuous BP   monitoring to lower BP 
rapidly yet not initially to a normal level. Normalization of BP 
immediately can lead to coronary and cerebral hypoperfusion 
syndromes. Therefore, BP should be lowered no more than 
25% in the first 2 hours, with gradual lowering over the first 
6 hours to a target of less than 160/100 mmHg.
In comparison with emergencies, hypertensive urgencies 
are situations requiring BP lowering within 24 hours in order 
to avoid target organ damage. Again, gradual lowering of 
BP is indicated, and can be obtained by administering oral 
agents in the setting of close follow-up.
Conclusion
In order to avoid the aforementioned hypertensive   “tsunami” 
and its subsequent cost to patients, and the general public and 
health care system overall, several barriers to achieving 
adequate BP control need to be addressed and overcome. 
The older hypertensive population with its higher incidence 
of multiple comorbidities requires an aggressive approach 
to choice of therapeutic regimen(s), intensity of therapy, 
consideration of the increased incidence of resistant HTN and 
ultimately, the goals of care (ie, which treatment guidelines 
will take precedence in a given patient’s circumstances). 
Likewise, the fact that there is no cure for this chronic con-
dition and that it is essentially “asymptomatic”, engenders 
poor adherence to recommended lifestyle changes and 
pharmacologic therapy. Additional obstacles to achieving 
recommended BP levels include poor health literacy, low 
financial status/cost of medications, poor or no health insur-
ance coverage, lack of adequate access to care and frequency 
of follow-up needed based on BP levels, and physicians’ 
overestimation of their own compliance with guidelines and 
achievement of BP goals.
With the goal of improving BP control in the burgeoning, 
older, hypertensive population, several quality improvement 
strategies have proven useful. Of these, a combination of a 
multidisciplinary approach, home and ambulatory BP moni-
toring, and patient education have proven the most effective. 
In this context, an interdisciplinary geriatric team is well 
suited to address all of these areas. Nurses trained in the 
management of HTN can provide feedback on the level of BP 
control, dieticians can review dietary compliance and provide 
education and reinforcement, pharmacists can evaluate for 
medication side effects/interactions and promote adherence, 
and social workers may be able to offer assistance with the 
financial burdens of obtaining and continuing medication. 
For those patients who are housebound, advanced practice 
nurses or physician assistants with physician support, can 
provide many of the same services as part of a similar mul-
tidisciplinary “home-based primary care” team. Employing 
these strategies should more than adequately address the most 
important factors in improving BP control, ie, frequent 
monitoring and follow-up measures (compliance,   education, 
maintaining long-term control of BP, and evaluation for 
adverse effects of treatment).
In summary, given the above conditions, the following 
general therapeutic recommendations apply in the elderly 
population:
•  Diuretics, starting at low doses and increased gradually, 
should be first-line in those patients without comorbid 
conditions.
•  In patients with diabetes mellitus (particularly those with 
proteinuria) the ACEIs (ARBs if there is cough with an 
ACEI) are considered first-line.
•  In those with systolic heart failure, a multi-pronged 
approach using ACEIs, diuretics (thiazide or loop, 
depending on renal function) and aldosterone antagonists 
is indicated.
•  The presence of CAD is an indication for the use of beta-
receptor antagonists (without intrinsic sympathomimetic 
activity).
•  Renal insufficiency with proteinuria from any cause 
should be managed with ACEIs, ARBs, and CCAs of 
the nondihydropyridine class.
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